


FROM SUGHRUE MION PLLC DC

(WED) 12. 4' 02 16:26/ST. 16:25/NO. 4260759780 P 1
2100 Pennsylvania Avenue, NW
Washington, DC 20037-3213
T 202.293.7060
F 202.293.7860



www.sughrue.com

FAX

Date December 4, 2002

To Examiner Misook Yu (GAU 160)

Of U.S. PATENT AND TRADEMARK OFFICE

Fax 703-746-7647

From Gordon Kit

Subject AMENDMENT/DECLARATION/DATE-STAMPED RECEIPT

Our Ref Q-61014 Your Ref USSN 09/670,568

Pages 13
(including cover sheet)

Please call attention to problems with this transmission by return fax or telephone. Thank you.

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR. PLEASE IMMEDIATELY NOTIFY US.

PLEASE ACKNOWLEDGE RECEIPT OF FACSIMILE: _____

16

PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re Application of:

Yoji IKAWA et al

Appln. No.: 09/670,568

Filed: September 27, 2000



Conf. No.: 5597

Group Art Unit: 1642

Examiner: Davis, N.

For: HUMAN p51 GENES AND GENE PRODUCTS THEREOF

PAPERS ENTITLED:

(1) AMENDMENT

(accompanied by an Appendix
and a Substitute Declaration
and Power of Attorney); and

(2) REQUEST FOR REFUND

(accompanied by the Monthly
Statement of Deposit Account
and reconciled checks (2)).

SUGHRUE MION, PLLC

2100 Pennsylvania Avenue, N.W.

Washington, D.C. 20037-3213

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

DOCKET NO.: Q-61014

ATTORNEY: GK/vf

Date: June 12, 2002

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yoji IKAWA et al

Conf. No.: 5597

Appln. No.: 09/670,568

Group Art Unit: 1642

Filed: September 27, 2000

Examiner: Davis, N.

For: HUMAN p51 GENES AND GENE PRODUCTS THEREOF

AMENDMENT

FILED

JUN 12 2002

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment is in response to the Office Action dated March 21, 2002, in the above-identified application, for which response is due on or before June 12, 2002.

The Patent Office is authorized to charge any fees necessary for the continued pendency of the above-identified application to our Deposit Account No. 19-4880.

Accordingly, please amend the above-identified application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, lines 10-25, delete in their entirety.

Page 2, lines 1-2, delete in their entirety, and insert therefor

--) The p53 protein was discovered as a nuclear protein binding to the large T antigen of the DNA tumor virus SV40 and its gene (p53 gene) has been cloned. At first, the p53 gene was considered to be an oncogene because the transfer of this gene